NCT00928486 · REGISTRY CONDITION SEARCH

A Safety Confirmation Study on Lenalidomide With Dexamethasone In Japanese Patients With Previously Treated Multiple Myeloma

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase: PHASE3
Status at capture: COMPLETED
Registry last update: 2019-11-20

To evaluate the safety and efficacy of lenalidomide with dexamethasone in Japanese patients with previously treated multiple myeloma.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Number of Participants Experiencing Treatment-Emergent Adverse Events (TEAE)

→

outcome · POSTED

Myeloma Response Rate

→

outcome · POSTED

Kaplan-Meier Estimates of Duration of Response (DoR)

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→

Who could take part

eligibility Criteria: Inclusion Criteria: * Must understand and voluntarily sign the informed consent form * Age ≥ 20 years at the time of signing the informed consent form * Subjects with previously treated multiple myeloma defined as follows: * Subjects must have received at least 1 prior anti-myeloma drug treatment regimen; and * Considered to have progression of disease (PD) that occurred either during or following the completion of the last anti-myeloma treatment regimen utilized prior to enrollment into this study * Measurable levels of M-protein in serum (greater than or equal to 0.5 g/dL \[5g/L\]) or urine (greater than or equal to 0.2 g excreted in a 24-hour collection sample) * Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 2 * Must be able to adhere to the study visit schedule and other protocol requirements * Females of childbearing potential (FCBP) must agree to use one or more of the following forms of contraception or abstain from heterosexual contact completely and have the male partners use a condom on the occasion of heterosexual contact in the following periods below: * For at least 28 days before starting study drug (in particular, the subject must abstain from heterosexual contact for 2 weeks prior to prescribing lenalidomide). * During the treatment phase (including the dose withholding period) For at least 28 days after the discontinuation/completion of the study drug (Methods of contraception) * Birth control pills * Intrauterine device (IUD) * Bilateral tubal ligation (FCBP must be referred to a health care provider who is familiar with contraceptive methods, if needed). * Male subject must agree to use a condom during sexual contact with female irrespective of pregnancy potential * Subjects must agree that study drug must be immediately discontinued, if pregnancy or a positive pregnancy test does occur in a female study subject or the partner of a male study subject during study participation Exclusion Criteria: * Pregnant or lactating females * Subjects with a history of acute myocardial infarction within the past 6 months before starting the study drugs * Subjects with any history or concurrent conditions of deep vein thrombosis or pulmonary embolus within the past 3 years before starting study drugs * Subjects with tuberculous diseases, herpes simplex keratitis, systemic mycosis or other active infectious diseases * Subjects with non-controlled diabetes, hypertension, digestive ulcer or glaucoma * Subjects with posterior subcapsular cataracts * Subjects with peripheral neuropathy of ≥Grade 2 * Subjects with any history or concurrent conditions which the Principal Investigator / subinvestigators consider inappropriate for participation in this study, and subjects with a serious disease or a mental disease, which is considered to become more risky if the subjects participate in this study. * Subjects with a history of desquamative (blistering) rash while taking thalidomide * Subjects with a history of using lenalidomide * Subjects who have used thalidomide within 28 days before starting the study drugs * Subjects with a history of hypersensitivity to dexamethasone * Subjects who discontinued treatment due to grade 3 or 4 toxicity from high dose dexamethasone * Subjects with a surgical wound after a visceral surgery performed recently * Subjects who have undergone radiation therapy within 14 days before starting the study drugs * Subjects who have used a chemotherapeutic agent, an immunomodulating agent or a study drug (a drug not commercially available) intended for the treatment of multiple myeloma (MM) within 28 days before starting the study drug * Subjects with any history or concurrent conditions of malignancies, other than MM, unless the subject has been free of the disease for 3 years: * Basal cell carcinoma of the skin, * Squamous cell carcinoma of the skin, * Carcinoma in situ of the cervix, * Carcinoma in situ of the breast, * Incidental histologic finding of prostate cancer Tumor, Lymph Nodes, Metastasis (TNM) stage of T1a or T1b) * Known human immunodeficiency virus (HIV) infection or HIV-1 positivity * Subjects who have been diagnosed as an hepatitis b virus (HBV) carrier * Subjects who are applicable to any of the following abnormal laboratory findings: * Absolute neutrophil count : \< 1,000 /μL (1.0×10\^9 /L) * Platelet count: \<75,000 /μL (75×10\^9 /L) * Aspartate aminotransferase (AST)/serum glutamic oxaloacetic transaminase (SGOT) or alanine aminotransferase (ALT)/serum glutamic-pyruvic transaminase (SGPT): \> 3.0 times the upper limit of the standard range * Creatinine clearance: \< 30 mL/min
healthy Volunteers: false
minimum Age: 20 Years
sex: ALL
std Ages: ADULT
OLDER_ADULT

Treatment arms and interventions

arm Groups

description
Lenalidomide 25mg by mouth (PO) once daily (QD) on Days 1-21 of each 28 day cycle; When creatinine (CrCl) clearance \<60 mL/min, the initial dose was 10mg and the dose could be increased to 15mg after 2 cycles if the investigator judged therapeutic effect was insufficient and tolerability was acceptable. Dexamethasone 40 mg by PO once QD on days 1-4, 9-12 and 17-20 of each 28 day cycle for the first 4 cycles and Days 1-4 for the remaining cycles beginning at Cycle 5.
intervention Names
Drug: Lenalidomide
Drug: Dexamethasone
label
Lenalidomide and Dexamethasone
type
EXPERIMENTAL

interventions

arm Group Labels
Lenalidomide and Dexamethasone
description
Lenalidomide 25mg PO for (days 1 - 21) of a 28-day cycle
name
Lenalidomide
other Names
CC-5013
Revlimid
type
DRUG
arm Group Labels
Lenalidomide and Dexamethasone
description
Dexamethasone 40 mg by mouth (PO) daily (QD) on days 1-4, 9-12 and 17-20 of each 28 day cycle
name
Dexamethasone
other Names
Decadron
type
DRUG

Study design

allocation

intervention Model

SINGLE_GROUP

masking Info

masking: NONE

primary Purpose

TREATMENT

Enrollment

count: 25
type: ACTUAL

Registered outcome plans (not posted results)

primary Outcomes

description
A TEAE was defined as any AE that started on or after the first dose of study drug, and within End of Study (EOS) (28 days after the last dose of study drug received). A serious AE (SAE) = any AE which results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability; is a congenital anomaly/birth defect; or constitutes an important medical event. The intensity of AEs were graded 1 to 5 according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0. For all other AEs not described in the CTCAE criteria, the intensity was assessed by the investigator as mild grade (Grade 1), moderate (grade 2), severe (grade 3), life-threatening (grade 4) or death (grade 5)
measure
Number of Participants Experiencing Treatment-Emergent Adverse Events (TEAE)
time Frame
Day 1 of study drug through 28 days after the last dose of study drug; maximum treatment duration was 60.3 weeks

secondary Outcomes

description
Overall myeloma response rate was determined by the investigator using the Myeloma Response Determination Criteria adapted from Bladé criteria. A responder is any patient who showed at least a partial response. Overall myeloma response rate is defined as the percentage of participants who achieved a Complete Response (CR), plus a Remission Response (RR), plus a Partial Response (PR). A CR is the disappearance of monoclonal paraprotein and maintained for ≥ 6 weeks. RR is a 75-99% reduction in the level of the serum monoclonal paraprotein compared to baseline; 90-99% reduction in 24-hr urinary light chain excretion. PR is a 50-74% reduction in the level of monoclonal paraprotein compared to baseline; 50-89% reduction in 24-hr urinary light chain excretion.
measure
Myeloma Response Rate
time Frame
From the time of the first dose of study drug to study completion; median duration on study was 42.1 weeks
description
Duration of response was defined as the time from the first observation of a response (CR, RR or PR) to the first documented disease progression or relapse. For participants who did not progress during the study, duration of response was censored at the last adequate response assessment showing evidence of no disease progression. Disease progression is defined as an increase in M-protein serum monoclonal paraprotein and/or urine paraprotein or evidence of bone marrow plasmacytosis and plasma cells, an appearance of new or existing soft tissue plasmacytomas, an appearance of new or existing lytic bone lesions and/or hypercalcemia \>11.5mg/dL
measure
Kaplan-Meier Estimates of Duration of Response (DoR)
time Frame
From the time of the first dose of study drug to study completion; the median duration on study was 42.1 weeks

Full study description

brief Summary: To evaluate the safety and efficacy of lenalidomide with dexamethasone in Japanese patients with previously treated multiple myeloma.

Source references

Source notices and limitations

Discovery and provenance

release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-1555384fc05b519e6aa4
requested nct id
NCT00928486
primary nct id
NCT00928486
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Plasma+Cell+Neoplasms&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
payload sha256
6f42e14595100459d5baee78f1b681145b5aa6bb3af71b49c292b87b4f632f68
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-1555384fc05b519e6aa4
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT00928486
occurrences
context exact
NCT00928486
end
11
exact text
NCT00928486
start
0
offset unit
unicode_code_points
query cond
Plasma Cell Neoplasms
query disease state id
ds-plasma-cell-neoplasms
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-plasma-cell-neoplasms-000.json
source file sha256
2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
source json pointer
/studies/574/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
4cab8b5cf00bd7478c7afa09b47799ddbc53b7feab007f99940d209236932bce
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Plasma+Cell+Neoplasms&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true

Preserved source evidence · Not medical advice